Affymetrix and Iconix Collaborate to Develop New Solutions for Assessing Drug Toxicity
09-Feb-2006
Together, Affymetrix' expression arrays and Iconix' analysis methods will provide detailed information on a drug candidate's toxicological liabilities and pharmacological properties. Using such tools, researchers will be able to quickly compare gene expression profiles to the Iconix' Drug Signatures(R) library to help predict the impact that gene expression changes may have on biological pathways critical to the body's toxic response to drugs.
Most read news
Topics
Organizations
Affymetrix
Iconix Pharmaceuticals
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.